SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 1,266.66 |
| Enterprise Value ($M) | 953.17 |
| Book Value ($M) | 530.94 |
| Book Value / Share | 4.29 |
| Price / Book | 2.39 |
| NCAV ($M) | 400.98 |
| NCAV / Share | 3.24 |
| Price / NCAV | 3.16 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.07 |
| Return on Assets (ROA) | -0.06 |
| Return on Equity (ROE) | -0.10 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 10.84 |
| Current Ratio | 11.93 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 815.97 |
| Assets | 945.93 |
| Liabilities | 414.99 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 277.25 |
| Operating Income | 0.89 |
| Net Income | 27.31 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 66.51 |
| Cash from Investing | -18.04 |
| Cash from Financing | -102.02 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Deep Track Biotechnology Master Fund, Ltd. | 13.50 | ||
| 13G/A | Kynam Capital Management, LP | 4.99 | -21.26 | |
| 13G/A | BlackRock, Inc. | 16.00 | 0.00 | |
| 13D/A | Deep Track Capital, LP | 13.60 | 42.03 | |
| 13G/A | State Street Corp | 5.90 | -19.01 | |
| 13G/A | Federated Hermes, Inc. | 4.70 | -45.81 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 238,651 | 1,168,911 | 20.42 | |
| 228,170 | 1,009,627 | 22.60 | |
| 178,197 | 1,178,120 | 15.13 | |
| 262,671 | 1,338,344 | 19.63 | |
| 218,463 | 1,310,028 | 16.68 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| DAWN – Day One Biopharmaceuticals, Inc. | DNLI – Denali Therapeutics Inc. |
| DSGN – Design Therapeutics, Inc. | EDIT – Editas Medicine, Inc. |
| ELVN – Enliven Therapeutics, Inc. |